newsfilter
← Latest News
GlobeNewswire·

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in Varseta-M Dose